10-Q: Ligand Pharma Q3 2025: Revenue Soars on Pelthos Deal, New Investments

Ligand Pharmaceuticals reported a significant increase in Q3 2025 revenue, driven by the Pelthos Transaction and strong royalty growth, alongside new strategic investments and a convertible senior notes offering.

Summary

• Total revenue and other income increased by 123% to $115.5 million in Q3 2025, compared to $51.8 million in Q3 2024.
• Year-to-date (YTD) 2025 total revenue and other income increased by 68% to $208.4 million, compared to $124.3 million in YTD 2024.
• Royalties increased by 47% to $46.6 million in Q3 2025, primarily due to increased sales of Filspari, Ohtuvayre, and Capvaxive.
• Captisol sales increased by 71% to $10.7 million in Q3 2025, driven by the timing of customer orders.
• Contract revenue and other income surged by 320% to $58.2 million in Q3 2025, largely attributable to $53.1 million in income from the Pelthos Transaction.
• Net income for Q3 2025 was $117.3 million, a significant improvement from a net loss of $7.2 million in Q3 2024.
• Diluted net income per share was $5.68 in Q3 2025, compared to a diluted net loss per share of $(0.39) in Q3 2024.
• Issued $460 million aggregate principal amount of 0.75% convertible senior notes due 2030, with net proceeds of approximately $445.1 million.
• Invested $7 million in Arecor for economic rights to AT220 and AT292 programs, along with warrants.
• Invested $25 million in Orchestra BioMed's late-stage cardiology programs, including a $5 million equity investment and $20 million in research and development funding.
• Cash, cash equivalents, and short-term investments totaled $664.5 million as of September 30, 2025, an increase of $408.4 million from December 31, 2024.

Sentiment

Score: 8

Explanation: The company reported exceptionally strong financial performance for Q3 2025, with a significant turnaround to net income and substantial revenue growth driven by strategic transactions and royalty increases. While R&D expenses increased due to new investments, the overall financial health and strategic positioning appear robust, indicating strong positive momentum.

Positives

• Total revenue and other income increased significantly by 123% in Q3 2025 and 68% YTD 2025, demonstrating strong top-line growth.
• Achieved a substantial net income of $117.3 million in Q3 2025, a significant turnaround from a net loss of $7.2 million in Q3 2024.
• Royalty revenue grew by 47% in Q3 2025, driven by strong performance from key products such as Filspari, Ohtuvayre, and Capvaxive.
• The Pelthos Transaction generated $53.1 million in income and a $5 million milestone payment following the commercial launch of Zelsuvmi.
• New strategic investments in Arecor and Orchestra BioMed expand the portfolio of future royalty streams and development programs.
• FDA approval of Lasix ONYU, the 17th Captisol-enabled product, entitles the company to milestone payments, royalties, and material sales revenue.
• Increased cash and short-term investments to $664.5 million as of September 30, 2025, providing robust liquidity and financial flexibility.
• The Revolving Credit Facility was increased to $125 million and its maturity date extended to September 12, 2028, enhancing access to capital.
• Positive Phase 2 study results for efdoralprin alfa (SAR447537) in alpha-1 antitrypsin deficiency emphysema were announced.
• FDA accepted Tzield for expedited review to delay progression of stage 3 type 1 diabetes and nominated it for the Commissioners National Priority Voucher (CNPV) pilot program.
• French National Agency of Medicines and Health Product Safety (ANSM) granted reimbursed compassionate access for Agenus' botensilimab plus balstilimab (Bot/Bal) in refractory MSS metastatic colorectal cancer.

Negatives

• Research and development expenses increased significantly by $15.3 million in Q3 2025 and $60.7 million YTD 2025, primarily due to funding arrangements for the Castle Creek and Orchestra transactions.
• Year-to-date 2025 saw a loss from short-term investments of $3.6 million, a notable decline from a gain of $98.9 million in YTD 2024, mainly due to an unrealized loss on Viking common stock of $14.0 million.
• Net cash provided by operating activities decreased substantially to $3.4 million in YTD 2025 from $68.6 million in YTD 2024, partially offset by R&D funding arrangements.
• Financial royalty assets impairment of $26.5 million was recorded in YTD 2024 due to Takeda's Soticlestat missing its Phase 3 primary endpoint.

Risks

• Forward-looking statements are inherently subject to risks and uncertainties, and actual results may differ materially from expectations.
• No material changes to the risk factors disclosed in Part I, Item 1A of the 2024 Annual Report were identified, indicating ongoing exposure to previously stated risks.
• Uncertainty exists regarding future results of operations and financial position, royalties and milestones under license agreements, Captisol material sales, product development, and product regulatory filings and approvals.
• The inability to retain key employees or enter into strategic partnerships could negatively impact business operations.
• Ongoing or future arbitration, litigation, or disputes with third parties may have a material adverse effect on the business.
• Legal proceedings include three civil complaints related to the National Prescription Opiate Litigation, which the company intends to vigorously defend.
• CyDex Pharmaceuticals, Inc. is involved in litigation against Bexson Biomedical, Inc. for alleged breach of a Captisol In Vivo Agreement, misuse of confidential information, and improper patent filings.
• Baxter Healthcare Corp. and CyDex Pharmaceuticals, Inc. filed a lawsuit against PH Health Limited for alleged infringement of the '773 patent related to a Captisol-enabled Nexterone ANDA filing.
• The unpredictability inherent in litigation means the outcome of these legal matters cannot be predicted with certainty.

Future Outlook

The company expects to utilize the remaining net proceeds from the convertible notes offering for general corporate purposes. Palvella plans to engage with the FDA in the first half of 2026 to discuss the Phase 2 study design for Qtorin rapamycin in angiokeratomas, with study initiation anticipated in the second half of 2026. Renalys Pharma anticipates topline results for sparsentan in IgA nephropathy in Q4 2025, in preparation for an NDA submission. The company believes its existing funds, cash generated from operations, and access to financing are sufficient to cover working capital, capital expenditures, debt service, research and development efforts, potential stock repurchases, and other strategic business initiatives, including acquisitions and investments.

Management Comments

• Our business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.
• Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner.
• We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue.
• We currently believe that none of the claims or actions pending against us is likely to have, individually or in aggregate, a material adverse effect on our business, financial condition or results of operations.

Industry Context

The biopharmaceutical industry continues to demonstrate dynamic activity in strategic partnerships, licensing agreements, and mergers and acquisitions, as evidenced by Ligand's Pelthos Transaction, and its investments in Arecor and Orchestra BioMed. The acquisition of Verona Pharma by Merck further highlights consolidation trends. The successful launch of new products like Zelsuvmi and Lasix ONYU, alongside positive clinical trial results for partnered programs such as efdoralprin alfa and Tzield, indicates a robust pipeline and a receptive market for innovative therapies. Regulatory advancements, including FDA expedited reviews and updated treatment guidelines for conditions like IgAN, play a crucial role in accelerating product commercialization and shaping market access within the sector.

Corporate Governance

Legal Proceedings

• Three civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes, designated as a Multi-District Litigation (MDL) captioned In Re: National Prescription Opiate Litigation. The company rejects all claims and intends to vigorously defend these matters.
• CyDex Pharmaceuticals, Inc. filed a Verified Complaint in the Delaware Court of Chancery against Bexson Biomedical, Inc., asserting claims for declaratory relief and breach of contract arising out of a Captisol In Vivo Agreement, alleging misuse of confidential information and materials, and improper patent applications. Briefing is scheduled to be complete by November 17, 2025.
• Baxter Healthcare Corp. and CyDex Pharmaceuticals, Inc. filed a lawsuit in the United States District Court for the District of New Jersey against PH Health Limited (a subsidiary of Endo, Inc.) for infringement of U.S. Patent No. 7,635,773, related to an Abbreviated New Drug Application (ANDA) referencing Captisol-enabled Nexterone.

Related Party Transactions

• Pelthos Therapeutics Inc. is considered a related party due to Ligand's significant equity interest and ongoing contractual arrangements.
• Ligand's CEO and director, Todd Davis, and Senior Vice President of Investment Operations, Richard Baxter, were appointed to Pelthos' board of directors following the Pelthos Transaction. Mr. Davis recused himself from the transaction's approval.
• Ligand invested $18 million in Pelthos concurrent with the Pelthos Transaction, receiving Pelthos Series A Convertible preferred shares and common shares.
• Ligand invested an additional $9 million in Pelthos' $18 million private convertible notes financing on November 6, 2025.

Stakeholder Impact

• Shareholders: Significant increase in net income and revenue, coupled with strategic investments and a capital raise, is likely to positively impact shareholder value. The convertible notes offering and associated warrants aim to manage potential dilution.
• Employees: No direct impact on employees was explicitly mentioned, but a growing company with expanding strategic investments generally provides stability and potential opportunities.
• Customers/Partners: Continued development and commercialization of Captisol-enabled products and licensed programs (e.g., Zelsuvmi, Lasix ONYU, Filspari) benefits partners through successful product launches and market penetration, and ultimately patients.
• Creditors: The issuance of $460 million in convertible senior notes increases the company's debt, but a strong cash position and an increased revolving credit facility provide robust liquidity and financial flexibility to meet obligations.

Next Steps

• Briefing for the CyDex vs. Bexson legal proceedings is expected to be complete by November 17, 2025.
• CyDex anticipates filing a reply brief in the Bexson counterclaim on November 17, 2025.
• Top-line results from Palvella's TOIVA Phase 2 trial are expected in mid-December 2025.
• Renalys Pharma expects topline results for sparsentan in IgA nephropathy in Q4 2025, followed by preparation for an NDA submission.
• Palvella plans to meet with the FDA in the first half of 2026 to discuss the proposed design of a Phase 2 study for Qtorin rapamycin in angiokeratomas.
• Study initiation for Qtorin rapamycin in angiokeratomas is anticipated in the second half of 2026.
• Pelthos convertible notes, in which Ligand invested, will mature on November 6, 2027.
• The Revolving Credit Facility's maturity date has been extended to September 12, 2028.
• The 0.75% convertible senior notes due 2030 will mature on October 1, 2030.

Key Dates

Recommendation

The company demonstrated exceptional financial performance in Q3 2025, with a substantial increase in revenue and a significant return to profitability. Strategic divestitures like the Pelthos Transaction generated considerable income, while new investments in Arecor and Orchestra BioMed expand future royalty streams. The strong cash position, successful product launches (Zelsuvmi, Lasix ONYU), and positive clinical trial updates for partnered programs (efdoralprin alfa, Tzield) indicate robust growth potential. The convertible notes offering strengthens the balance sheet for future strategic initiatives, and the call spread overlay helps manage potential dilution. Despite increased R&D expenses, the overall outlook is highly positive, suggesting strong upside for investors.

Keywords

Biopharmaceutical, Royalties, Licensing, Captisol, Drug Development, SEC Filing, 10-Q, Financial Results, Biotech, Pharmaceuticals, Investments, Milestones, Corporate Governance, Risk Management, Convertible Notes